Abstract
Dyslipidemia, one of the major disadvantages of use of protease inhibitor (PI), is a risk factor for cardiovascular disease in HIV-infected patients receiving antiretroviral treatment. Little is known about the effect of a switch from another PI to unboosted atazanavir (ATV) on the lipid profile. The aim of this study was to evaluate changes in the lipid profile after switching from another PI to either unboosted or boosted ATV in HIV-infected Koreans. We retrospectively collected data on the serum lipid profile at the time of the switch (week 0), and weeks 12 and 24 after the switch, as well as clinical characteristics at week 0 in a total of 27 patients. Triglyceride (TG) showed a significant decrease at weeks 12 and 24 in all patients (196 vs. 174 mg/dL, P=0.048 and 196 vs. 150 mg/dL, P=0.021, respectively). However, these effects were only observed in the unboosted ATV group (N=14; 239 vs. 125 mg/dL, P=0.017 and 239 vs. 87 mg/dL, P=0.021, respectively). For total cholesterol, only the unboosted ATV group at 24 weeks showed a significant decrease (184 vs. 158 mg/dL, P=0.031). No significant changes were observed in LDL- and HDL-cholesterol at weeks 12 and 24 in both the unboosted and boosted ATV groups. These results suggest that changing to unboosted ATV from another PI may ameliorate high TG and total cholesterol in HIV-infected Koreans.
| Original language | English |
|---|---|
| Pages (from-to) | 377-381 |
| Number of pages | 5 |
| Journal | Infection and Chemotherapy |
| Volume | 44 |
| Issue number | 5 |
| DOIs |
|
| Publication status | Published - 2012 Dec 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Infectious Diseases
- Pharmacology (medical)
Cite this
}
Lipid profile changes after switch to atazanavir from other protease inhibitor-based combined antiretroviral treatment in hiv-infected korean. / Baek, Ji Hyeon; Song, Young Goo; Kim, Chang Oh; Jeong, Su Jin; Koo, Nam Soo; Kim, Hye Won; Han, Sang Hoon; Choi, Jun Yong; Kim, June Myung.
In: Infection and Chemotherapy, Vol. 44, No. 5, 01.12.2012, p. 377-381.Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - Lipid profile changes after switch to atazanavir from other protease inhibitor-based combined antiretroviral treatment in hiv-infected korean
AU - Baek, Ji Hyeon
AU - Song, Young Goo
AU - Kim, Chang Oh
AU - Jeong, Su Jin
AU - Koo, Nam Soo
AU - Kim, Hye Won
AU - Han, Sang Hoon
AU - Choi, Jun Yong
AU - Kim, June Myung
PY - 2012/12/1
Y1 - 2012/12/1
N2 - Dyslipidemia, one of the major disadvantages of use of protease inhibitor (PI), is a risk factor for cardiovascular disease in HIV-infected patients receiving antiretroviral treatment. Little is known about the effect of a switch from another PI to unboosted atazanavir (ATV) on the lipid profile. The aim of this study was to evaluate changes in the lipid profile after switching from another PI to either unboosted or boosted ATV in HIV-infected Koreans. We retrospectively collected data on the serum lipid profile at the time of the switch (week 0), and weeks 12 and 24 after the switch, as well as clinical characteristics at week 0 in a total of 27 patients. Triglyceride (TG) showed a significant decrease at weeks 12 and 24 in all patients (196 vs. 174 mg/dL, P=0.048 and 196 vs. 150 mg/dL, P=0.021, respectively). However, these effects were only observed in the unboosted ATV group (N=14; 239 vs. 125 mg/dL, P=0.017 and 239 vs. 87 mg/dL, P=0.021, respectively). For total cholesterol, only the unboosted ATV group at 24 weeks showed a significant decrease (184 vs. 158 mg/dL, P=0.031). No significant changes were observed in LDL- and HDL-cholesterol at weeks 12 and 24 in both the unboosted and boosted ATV groups. These results suggest that changing to unboosted ATV from another PI may ameliorate high TG and total cholesterol in HIV-infected Koreans.
AB - Dyslipidemia, one of the major disadvantages of use of protease inhibitor (PI), is a risk factor for cardiovascular disease in HIV-infected patients receiving antiretroviral treatment. Little is known about the effect of a switch from another PI to unboosted atazanavir (ATV) on the lipid profile. The aim of this study was to evaluate changes in the lipid profile after switching from another PI to either unboosted or boosted ATV in HIV-infected Koreans. We retrospectively collected data on the serum lipid profile at the time of the switch (week 0), and weeks 12 and 24 after the switch, as well as clinical characteristics at week 0 in a total of 27 patients. Triglyceride (TG) showed a significant decrease at weeks 12 and 24 in all patients (196 vs. 174 mg/dL, P=0.048 and 196 vs. 150 mg/dL, P=0.021, respectively). However, these effects were only observed in the unboosted ATV group (N=14; 239 vs. 125 mg/dL, P=0.017 and 239 vs. 87 mg/dL, P=0.021, respectively). For total cholesterol, only the unboosted ATV group at 24 weeks showed a significant decrease (184 vs. 158 mg/dL, P=0.031). No significant changes were observed in LDL- and HDL-cholesterol at weeks 12 and 24 in both the unboosted and boosted ATV groups. These results suggest that changing to unboosted ATV from another PI may ameliorate high TG and total cholesterol in HIV-infected Koreans.
UR - http://www.scopus.com/inward/record.url?scp=84872845218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872845218&partnerID=8YFLogxK
U2 - 10.3947/ic.2012.44.5.377
DO - 10.3947/ic.2012.44.5.377
M3 - Comment/debate
AN - SCOPUS:84872845218
VL - 44
SP - 377
EP - 381
JO - Infection and Chemotherapy
JF - Infection and Chemotherapy
SN - 2093-2340
IS - 5
ER -